ANU Stock Chart & Stats
€1.79
€0.09(5.04%)
At close: 4:00 PM EDT
€1.79
€0.09(5.04%)
Day’s Range― - ―
52-Week Range€1.10 - €4.10
Previous CloseN/A
Volume0.00
Average Volume (3M)19.00
Market Cap
€3.61M
Enterprise Value€3.77
Total Cash (Recent Filing)€992.43K
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.73
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.21
Shares Outstanding1,816,565
10 Day Avg. Volume0
30 Day Avg. Volume19
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.75
Price to Sales (P/S)0.00
P/FCF Ratio-1.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.09
Revenue Forecast (FY)€2.02M
Bulls Say, Bears Say
Bulls Say
Near-zero DebtVery low leverage limits interest and refinancing pressure, preserving financial flexibility while the company funds clinical development. This gives management more room to allocate capital toward its pipeline and reduces the balance-sheet risk that often amplifies setbacks for early-stage biotechnology companies.
Focused Therapeutic PipelineA focused small-molecule pipeline aimed at kidney and metabolic diseases can concentrate research resources around defined clinical needs. Continued specialization may help the company build expertise and advance differentiated candidates through development instead of spreading effort across unrelated therapeutic areas.
Equity Funding Supports DevelopmentAccess to equity financing has enabled XORTX to continue research, clinical trials, and operations despite having no marketed product revenue. Continued funding capacity can sustain pipeline advancement over the next several months, although it also creates dilution exposure for existing shareholders.
Bears Say
No Product RevenueThe absence of recurring product revenue means the company has not yet demonstrated commercial demand or an operating engine that can fund development internally. Until a therapy reaches market and generates sales, financial performance will remain tied to clinical progress and outside capital.
Recurring Operating LossesPersistent losses and negative gross profit show that operating costs currently exceed any economic output from the business. The re-widening of TTM losses indicates profitability remains structurally distant, limiting retained capital and increasing dependence on successful future development outcomes.
Persistent Cash BurnOngoing negative operating and free cash flow confirms that the company is not self-funding and continues consuming capital to operate. Worsening recent free-cash-flow performance may shorten funding runway and increase the likelihood of additional financing before commercial revenues emerge.
XORTX Therapeutics Inc News
ANU FAQ
What was XORTX Therapeutics Inc’s price range in the past 12 months?
XORTX Therapeutics Inc lowest stock price was €1.09 and its highest was €4.10 in the past 12 months.
What is XORTX Therapeutics Inc’s market cap?
XORTX Therapeutics Inc’s market cap is €3.61M.
When is XORTX Therapeutics Inc’s upcoming earnings report date?
XORTX Therapeutics Inc’s upcoming earnings report date is Nov 12, 2026 which is in 64 days.
How were XORTX Therapeutics Inc’s earnings last quarter?
XORTX Therapeutics Inc released its earnings results on Aug 15, 2026. The company reported -€0.904 earnings per share for the quarter.
Is XORTX Therapeutics Inc overvalued?
According to Wall Street analysts XORTX Therapeutics Inc’s price is currently Overvalued.
Does XORTX Therapeutics Inc pay dividends?
XORTX Therapeutics Inc does not currently pay dividends.
What is XORTX Therapeutics Inc’s EPS estimate?
XORTX Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does XORTX Therapeutics Inc have?
XORTX Therapeutics Inc has 1,816,565 shares outstanding.
What happened to XORTX Therapeutics Inc’s price movement after its last earnings report?
XORTX Therapeutics Inc reported an EPS of -€0.904 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of XORTX Therapeutics Inc?
Currently, no hedge funds are holding shares in DE:ANU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
XORTX Therapeutics Inc
Based in Vancouver, Canada, XORTX Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering and bringing to market treatments for a variety of conditions, including progressive kidney disorders, diabetes, insulin resistance, metabolic syndrome, and infections. The company's pipeline includes XRx-008, a late-stage clinical program addressing autosomal dominant polycystic kidney disease; XRx-101, an agent designed to reduce uric acid levels in COVID-19 patients to prevent acute kidney injury and its associated health issues; and XRx-221, a series of xanthine oxidase inhibitor candidates aimed at treating diabetic nephropathy. Furthermore, XORTX Therapeutics collaborates with the Icahn School of Medicine to research the occurrence of acute kidney injury and elevated uric acid in patients hospitalized with COVID-19.